JAN - JanOne Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1300
-0.0600 (-5.04%)
At close: 03:58PM EDT
1.0800 -0.05 (-4.42%)
After hours: 05:47PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.1900
Open1.1000
Bid1.1100 x 3200
Ask1.1400 x 800
Day's Range1.0800 - 1.1600
52 Week Range0.8600 - 4.1900
Volume44,150
Avg. Volume386,779
Market Cap4.085M
Beta (5Y Monthly)1.84
PE Ratio (TTM)
EPS (TTM)0.0000
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
43% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for JAN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PR Newswire

    JanOne Completes Pre-IND Meeting with FDA on Jan123

    JanOne (Nasdaq: JAN), the biopharmaceutical innovator specializing in non-addicting painkillers and new treatments for the causes of pain, has completed a successful pre-IND meeting with the FDA regarding Jan123. Jan123 is the company's unique oral delivery of low dose naltrexone formulated to treat complex regional pain syndrome, an orphan disease of severe, debilitating impact.

  • PR Newswire

    JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

    JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Saturday, April 15th on the topic of Innovation in Pain Medicine and will be discussing the drug development programs at JanOne. JanOne is a biotech company that is developing two different late-stage non-opioid drug candidates: JAN 101 is designed to treat peripheral artery disease that was also shown to improve pain in pat

  • PR Newswire

    JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

    JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced the closing of its previously announced registered direct offering of 361,000 shares of the Company's common stock at a purchase price of $1.17 per share of common stock priced at-the-market under Nasdaq rules.

  • PR Newswire

    JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

    JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the hiring of John N. Bonfiglio, PhD, as interim president of its JanOne Biotech subsidiary. JanOne Biotech focuses on pain management for diabetic neuropathy, Peripheral Artery Disease (PAD), and other chronic pain conditions using innovative treatments developed by JanOne Inc.

  • PR Newswire

    JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

    JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the Company's common stock at a purchase price of $1.17 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about Mar

  • PR Newswire

    JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

    JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced that on March 9, 2023 they entered into a Stock Purchase Agreement with VM7, a Delaware corporation, under which VM7 agreed to acquire all of the outstanding equity interests of ARCA Recycling, Inc, Customer Connexx LLC and ARCA Canada Inc. Virland Johnson, who has served as ARCA Recycling's CFO and COO for several years is the principal

  • PR Newswire

    JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians

    JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present data on two of its investigational pharmaceutical compounds at the American Society of Interventional Pain Physicians (ASIPP) annual meeting in Washington DC in March, 2023.

  • PR Newswire

    JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management

    JanOne (Nasdaq: JAN), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk of addiction, held meetings at New York's Nasdaq MarketSite to review strategic plans and to facilitate integration of recently-acquired Soin Therapeutics.

  • PR Newswire

    JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC

    JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the max

  • PR Newswire

    JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC

    JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has executed a term sheet to acquire Soin Therapeutics LLC and its product, a patent-pending, novel formulation of low dose naltrexone. The product, that JanOne will name Jan123, is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), a severe, chronic pain generally affecting the arms or legs. There are no truly ef

  • PR Newswire

    ARCA Recycling, a Subsidiary of JanOne Inc., Unveils New Logo and Website

    ARCA Recycling, Inc. (ARCA), a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), unveiled a new logo that aligns its visual identity with the innovative and environmentally responsible services it offers. While ARCA's core mission to deliver best-in-class energy efficiency and environmental protection programs remains unchanged, the company has expanded its customer base in recent years. ARCA has significantly grown its commercial recycling business and is working to expand options for respo

  • PR Newswire

    JanOne Inc. Announces an Improved Formulation of JAN101

    JanOne Inc. ("JanOne") (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by Dr. Maureen Donovan at the University of Iowa that will allow for an improved formulation of JAN101. JAN101 (formerly known as TV1001SR), is a potential treatment for peripheral artery disease (PAD), a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide.